[Fever and cavitary infiltrate in a renal transplant recipient].
Aspergillus infection is a rare but devastating complication following organ transplantation with high mortality rate. Aspergillus fumigatus is the most common cause of invasive aspergillosis. This fungus is present in the environment worldwide. Aspergillus infection is mainly acquired by inhalation of spores and several nosocomial infections in transplant recipient have been associated with construction work at hospitals. Risk factors for invasive aspergillosis include administration of steroid boluses, history of cytomegalovirus infection, neutropenia and prolonged antibiotic use after transplantation. Successful treatment depends on three factors: early diagnosis, aggressive antifungal therapy and decrease or removal of immunosuppression. Amphotericin deoxycholate has been the standard treatment for many years but lipid preparations for amphotericin are now used due to their significantly fewer adverse effects. A number of new antifungal drugs are now being developed including new azoles such as voriconazol and echinocandin. Invasive aspergillosis has a high mortality rate more than 95% when cerebral dissemination is demonstrated. We report the case of a 47 years old woman who received a cadaveric renal graft and developed pulmonary aspergillosis with fulminant cerebral dissemination two months later. The diagnosis of pulmonary aspergillosis was by culture isolation obtained from bronchioalveolar lavage. Removal of immunosuppresive agents and liposomal amphotericin B therapy were started shortly after admission. Brain CT scan performed on the 12th day showed cerebral dissemination. The recipient died two days later. Our patient had several risk factors such as the administration of steroid boluses and cytomegalovirus infection. Invasive aspergillosis must be always included in the differential diagnosis of fever and pulmonary disease in the renal transplant recipient.
Rocamora
N
N
Servicio de Nefrología, Hospital General Universitario de Alicante, Alicante. cifu1@airtel.net
Tormo
A Ma
AM
Franco
A
A
Alvarez Avellán
L
L
Olivares
J
J
D000666:Amphotericin B / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000302:isolation & purification*; D003428:Cross Infection / Q000209:etiology* / Q000382:microbiology; D016572:Cyclosporine / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000150:complications; D017809:Fatal Outcome; D005260:Female; D005334:Fever / Q000209:etiology*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008081:Liposomes; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D020953:Neuroaspergillosis / Q000188:drug therapy / Q000209:etiology; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D016891:Polycystic Kidney, Autosomal Dominant / Q000601:surgery; D011241:Prednisone / Q000009:adverse effects; D012307:Risk Factors
D007166:Immunosuppressive Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B; D016572:Cyclosporine; D009173:Mycophenolic Acid; D011241:Prednisone